Description

Product Description

Daratumumab is a recombinant human monoclonal IgG1κ antibody that selectively binds to CD38, a transmembrane glycoprotein expressed on plasma cells, immune cells, and various hematopoietic lineages. In laboratory research, daratumumab serves as a critical tool to investigate CD38-dependent mechanisms, including cell surface receptor signaling, enzymatic modulation, and immune cell-mediated cytotoxicity.

The antibody mediates multiple biological effects through its Fc region, enabling interactions with immune effector cells and complement proteins. In experimental settings, daratumumab is used to study antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), and antibody-dependent cellular phagocytosis (ADCP) in cell lines, primary cells, and animal models.

Laboratory applications include:

• Plasma cell biology studies: Assessing survival, proliferation, and apoptosis of CD38-expressing cells.

• Immune cell modulation: Investigating natural killer (NK) cell, macrophage, and monocyte-mediated cytotoxicity.

• Signal transduction research: Exploring CD38 receptor signaling and downstream enzymatic activity such as NADase function.

• Combination studies: Evaluating synergistic effects with other monoclonal antibodies, cytokines, or experimental compounds.

• Preclinical pharmacology: Modeling in vivo biodistribution, receptor occupancy, and immunomodulatory effects.

Daratumumab is supplied as a sterile, research-grade solution or lyophilized powder, typically at high purity (≥95%), suitable for in vitro assays, flow cytometry, cytotoxicity experiments, and preclinical research models. Analytical characterization includes protein concentration verification, SDS-PAGE, mass spectrometry, and binding assays to ensure reproducibility and high-quality experimental outcomes.

Its specificity for CD38 and well-characterized effector functions make daratumumab an essential reagent in laboratory studies of hematopoietic regulation, immune cell cytotoxicity, and CD38 biology.

Product Specifications

Mechanism of Action

Daratumumab binds specifically to CD38, a glycoprotein expressed on plasma cells and various immune cell types. Its mechanism of action in research is mediated primarily by three pathways:

1. Antibody-Dependent Cellular Cytotoxicity (ADCC)

Through its Fc region, daratumumab engages NK cells and other effector cells, triggering cytotoxic activity against CD38-expressing cells in experimental models.

2. Complement-Dependent Cytotoxicity (CDC)

Binding to CD38 recruits complement proteins, activating the complement cascade to induce cell lysis in vitro or in animal studies.

3. Antibody-Dependent Cellular Phagocytosis (ADCP)

Daratumumab opsonizes target cells, promoting phagocytosis by macrophages and monocytes, providing mechanistic insight into immune-mediated clearance.

Additional Research Applications

• Modulation of NAD+ metabolism and calcium signaling via CD38 enzymatic activity.

• Investigation of receptor clustering, internalization, and downstream signaling pathways.

• Studies of immune checkpoint interactions and immunomodulatory mechanisms.

In vitro and preclinical research consistently demonstrate that daratumumab’s specificity and effector functions make it a versatile tool for studying CD38 biology, hematopoietic regulation, and immune cell-mediated cytotoxicity.

Side Effects

In laboratory research, daratumumab demonstrates minimal off-target effects at experimental concentrations. Observed effects may include transient changes in cell viability or immune cell activation dependent on assay conditions. Researchers should maintain proper experimental controls and avoid clinical application. Daratumumab is not intended for human or veterinary use outside laboratory research.

Keywords

Daratumumab, Anti-CD38 monoclonal antibody, immunological research, plasma cell studies, ADCC, CDC, ADCP, hematopoietic research, laboratory research protein, high-purity monoclonal antibody, immune cell modulation, factory peptide supplier, peptide wholesale China, cosmetic raw material manufacturer, low-price peptide supplier, China peptide manufacturer, OEM & bulk peptide production

Shipping Guarantee

All Daratumumab shipments of Daratumumab are handled using validated cold-chain logistics to preserve protein integrity and bioactivity. Each package is sealed in sterile, moisture-proof containers with secondary protective wrapping and continuous temperature monitoring. Products are shipped via express international couriers with full tracking and insurance coverage, ensuring delivery without degradation or aggregation.

Trade Assurance

We Daratumumab guarantee the authenticity and high purity (≥95%) of Daratumumab. Each batch undergoes stringent quality control, including protein concentration verification, SDS-PAGE, mass spectrometry, and binding activity assays. A Certificate of Analysis (CoA) is provided for every batch. Our trade assurance policy ensures replacement or refund for any deviation from listed specifications, including purity, stability, or formulation integrity.

Payment Support

We Daratumumab provide secure and flexible global payment options, including PayPal, major credit cards (Visa, MasterCard, American Express), telegraphic transfer (T/T), and cryptocurrencies (USDT, Bitcoin, Ethereum). All transactions are encrypted and verified, ensuring confidentiality and fund security.

Disclaimer

All Daratumumab products are intended for laboratory research use only. They are not drugs, medical devices, or diagnostics, and should not be administered to humans or animals. Researchers must comply with institutional biosafety and chemical safety guidelines. Information provided is for scientific reference only and does not imply therapeutic efficacy, safety, or regulatory approval.